River & Mercantile Asset Management LLP bought a new stake in Cerus Co. (NASDAQ:CERS) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 320,723 shares of the biotechnology company’s stock, valued at approximately $1,802,000. River & Mercantile Asset Management LLP owned 0.23% of Cerus as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. SG Americas Securities LLC raised its position in Cerus by 23.9% in the first quarter. SG Americas Securities LLC now owns 16,317 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 3,151 shares during the period. Aperio Group LLC purchased a new stake in Cerus in the second quarter valued at $27,000. Prudential Financial Inc. raised its position in Cerus by 20.7% in the second quarter. Prudential Financial Inc. now owns 34,297 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 5,880 shares during the period. Swiss National Bank raised its position in Cerus by 3.0% in the second quarter. Swiss National Bank now owns 254,800 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 7,500 shares during the period. Finally, Raymond James Trust N.A. raised its position in Cerus by 57.1% in the second quarter. Raymond James Trust N.A. now owns 22,000 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 8,000 shares during the period. Institutional investors own 72.94% of the company’s stock.

A number of research firms have commented on CERS. Zacks Investment Research upgraded Cerus from a “sell” rating to a “hold” rating in a research report on Monday. Stephens began coverage on Cerus in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 target price on the stock. Stifel Nicolaus began coverage on Cerus in a research report on Tuesday, August 27th. They issued a “buy” rating and a $7.00 target price on the stock. ValuEngine upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub downgraded Cerus from a “hold” rating to a “sell” rating in a report on Friday, October 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.63.

Shares of CERS stock traded up $0.01 on Wednesday, hitting $4.46. The stock had a trading volume of 6,721 shares, compared to its average volume of 864,617. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.67 and a quick ratio of 2.33. The firm has a market capitalization of $652.49 million, a P/E ratio of -10.14 and a beta of 1.64. Cerus Co. has a 1 year low of $4.41 and a 1 year high of $7.06. The company’s 50 day moving average price is $5.14 and its 200-day moving average price is $5.44.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01). The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. Cerus had a negative return on equity of 85.73% and a negative net margin of 98.69%. The company’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) earnings per share. On average, equities analysts forecast that Cerus Co. will post -0.48 EPS for the current year.

In other news, SVP Carol Moore sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $5.33, for a total transaction of $159,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Richard J. Benjamin sold 16,444 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $5.01, for a total value of $82,384.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 74,903 shares of company stock valued at $394,513. Insiders own 7.26% of the company’s stock.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading: Overbought

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.